New TRU NIAGEN PRO Launched for Expansive Distribution by Healthcare Practitioners
September 20 2018 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based,
nutraceutical company devoted to improving the way people age with
its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®,
today announced the launch of TRU NIAGEN PRO (60ct, 300mg per
capsule), a partnership with Natural Partners Fullscript, and a new
online NAD education hub for healthcare practitioners.
Tru Niagen Pro, which will be available exclusively for sale
through healthcare practitioners, is the first of its kind,
offering 60 capsules – each delivering 300 mg of Niagen®
nicotinamide riboside (NR).
Dr. Phillip Milgram, Medical Director of the NAD Treatment
Center in San Diego, CA, commented, “I have dedicated my career to
increasing patients’ NAD levels for multiple medical indications,
health and longevity. We are very excited to offer Tru Niagen
Pro through our clinic. The growing body of science pointing
to the importance of maintaining NAD levels via the use of daily
supplementation of clinically proven precursors such as NR
continues to build, and we are delighted to be associated with
ChromaDex, the pioneers of NR development. We have a clinically
proven dose of NR to deliver an effective increase in NAD in a
single capsule.”
“NAD is required for all cells in the body to function,” says
Dr. Alyssa Dweck, OB/GYN and Assistant Clinical Professor in the
Department of Obstetrics, Gynecology, and Reproductive Science at
the Mount Sinai School of Medicine. “I recommend Tru Niagen to my
patients.”
In addition to offering Tru Niagen Pro direct to practitioners,
ChromaDex has entered into a newly signed distribution agreement
with Natural Partners Fullscript (Scottsdale, AZ), making Tru
Niagen products available to their extensive network of over 40,000
healthcare practitioners.
Fran Towey, Natural Partners Fullscript CEO commented, “Tru
Niagen uniquely addresses the most critical issues facing patients
today and is proving to make a real positive difference in people’s
lives. We’re excited to be partnering with ChromaDex to bring its
innovation to our Natural Partners Fullscript community as well as
to bring Tru Niagen Pro exclusively to healthcare
practitioners.”
ChromaDex CEO Robert Fried notes, “We are delighted to be
associated with Natural Partners Fullscript. They are the leaders
and innovators in the healthcare practitioner channel and will help
us bring the Tru Niagen brand to this important and influential
community.”
Healthcare practitioners can also now have access to convenient
online wholesale purchasing as well as a practitioner-exclusive
education hub with a searchable, categorized database of the over
100 published pre-clinical and clinical studies detailing the
ability of NAD and NR to support human health.
For additional information on the science supporting TRU NIAGEN
visit www.truniagen.com.
About TRU NIAGEN®:TRU NIAGEN® is a branded
dietary supplement brought to market by key nicotinamide riboside
innovator and patent holder, ChromaDex. NIAGEN® nicotinamide
riboside (NR), also supplied by ChromaDex, is the sole active
ingredient in TRU NIAGEN®. Multiple clinical trials demonstrate
NIAGEN® is proven to boost NAD (nicotinamide adenine dinucleotide)
levels, which decline with age. Only NIAGEN® has twice been
successfully reviewed under FDA's new dietary ingredient (“NDI”)
notification program, and has also been successfully notified to
the FDA as generally recognized as safe (“GRAS”).
About ChromaDex:ChromaDex Corp. is an
integrated, global nutraceutical company devoted to improving the
way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN® nicotinamide
riboside, sold directly to consumers as TRU NIAGEN®, is backed with
clinical and scientific research, as well as extensive IP
protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex
maintains a website at www.chromadex.com to which ChromaDex
regularly posts copies of its press releases as well as additional
and financial information about the Company.
Forward-Looking Statements:
This release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of
1934, as amended. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects", "anticipates", "intends", "estimates", "plans",
"potential", "possible", "probable", "believes", "seeks", "may",
"will", "should", "could" or the negative of such terms or other
similar expressions. More detailed information about ChromaDex and
the risk factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 30, 2017, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof. ChromaDex provided research materials and a portion of
the grant funding as a collaborator for the study.
ChromaDex Media Contact:Alex Worsham, Director
of Strategic Partnerships949-648-3775alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Sr. Director of FP&A and Investor Relations(949)
600-9727briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024